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Abstract: Coumarins are naturally occurring molecules with a versatile range of activities. Their struc-
tural and physicochemical characteristics make them a privileged scaffold in medicinal chemistry
and chemical biology. Many research articles and reviews compile information on this important
family of compounds. In this overview, the most recent research papers and reviews from 2020 are
organized and analyzed, and a discussion on these data is included. Multiple electronic databases
were scanned, including SciFinder, Mendeley, and PubMed, the latter being the main source of
information. Particular attention was paid to the potential of coumarins as an important scaffold in
drug design, as well as fluorescent probes for decaging of prodrugs, metal detection, and diagnostic
purposes. Herein we do an analysis of the trending topics related to coumarin and its derivatives in
the broad field of drug discovery.
Keywords: coumarins; biological applications; drug discovery; fluorescent probes
1. Introduction
Coumarins are molecules that belong to a very special family. Their conjugated double
ring system makes them interesting molecules for different fields of research. Coumarins
can be found in industry as cosmetics and perfume ingredients, as food additives, and
especially in the pharmaceutical industry in the synthesis of a large number of synthetic
pharmaceutical products [1]. This last application is the main focus of our overview.
Coumarin (Figure 1) is found in nature in a wide variety of plants, particularly in high
concentration in the tonka bean (Dipteryx odorata). It can also be found in sweet woodruff
(Galium odoratum), vanilla grass (Anthoxanthum odoratum), and sweet grass (Hierochloe
odorata), among others. This explains the great interest in the extraction and characterization
techniques of natural coumarins, and in the synthesis of their derivatives. In addition, the
simplicity of its chemical backbone is very attractive, as well as the reactivity of the benzene
and pyrone rings. Conjugated double bonds are responsible for an electronic environment
that plays a very important role in this family of compounds.




Figure 1. Basic classification of coumarins: chemical structures of the three main classes. 
2. Discussion 
Searching for the word “coumarin” in Mendeley, PubMed, and SciFinder in early 
November 2020, and filtering by year “2020”, more than a thousand references appeared. 
Another search was conducted in late December to include as much information as pos-
sible in this manuscript. A diversity of journals from different fields publishes research 
articles and reviews related to the biological interest of both plant extracts containing cou-
marins and/or synthetic molecules based on this scaffold. Hybrid molecules containing 
different pharmacophores [2,3] like piperazines or pyrazolines [4] are at the top of the list. 
For simplicity, in the current review the information is organized taking into account the 
potential pharmacological/biological applications of coumarin derivatives. 
2.1. Anticancer Activity 
The activity of coumarins as anticancer agents is at the top of reviews published in 
2020 [5–8], as well as research papers. Potent inhibitors (Figure 2, general structure I) of 
aldo–keto reductase (AKR) presenting an iminocoumarin scaffold, with activities between 
25 and 56 nM, have been described for the treatment of prostatic cancer [9]. The design of 
sulfamide 3-benzylcoumarin hybrids bearing an oxadiazole ring at position 7 (Figure 2, 
general structure II) has allowed the preparation of new multitarget mitogen-activated 
protein kinase (MEK) inhibitors and nitric oxide (NO) donors, both with antiproliferative 
properties [10]. In other cases, the anticancer profile has been directed to other targets. 
Such is the case of new inhibitors of cyclin-dependent kinases, specifically CDK9, design-
ing hybrids that incorporate an aminopyrimidine fragment to coumarin, both pharmaco-
phores of known activity on these therapeutic targets [11]. We highlight here compound 
III (Figure 2), with high activity and selectivity for these receptors in comparison with 
other kinases. 
Other important targets for cancer treatment, especially lymphomas, are histone 
deacetylases (HDACs). A series of coumarins (Figure 2, general structure IV) exhibiting a 
hydroxamate structure similar to HDACi vorinostat (SAHA) has been published [12]. The 
compounds show inhibitory activity in the nanomolar range, being higher in the case of 
propyl or methoxypropyl derivatives. 
In addition, it is worth highlighting the design of hybrids in which one part of the 
molecule provides fluorescent properties, and another provides therapeutic action 
(theranostic). Such is the case of the fusion of a 7-aminocoumarin fluorescent ring with a 
chalcone fragment (Figure 2, compound V). This molecule is an inhibitor of thioredoxin 
reductases (TrxRs), presenting high antitumor activity (IC50 = 3.6 μM), and is also used as 
a diagnostic agent [13]. Coumarin scaffold fluorescence is being explored extensively in 
biomedicine, as described at the end of this review. 
The preparation of photo-triggered drug delivery systems (PTDDSs, Figure 2, gen-
eral structure VI) has also been described, in which the chlorambucil pharmacophore is 
incorporated into more complex carbazole–coumarins (electron donor and electron accep-
tor fragments, respectively), carriers of a mitochondrial triphenylphosphonium ligand. 
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This review is based on the most relevant literature that comprises new data from
recent research articles and overviews on the development of new therapeutic solutions
and fluorescent probes based on the coumarin scaffold. The research articles and reviews
organized to prepare this manuscript have been compiled from various electronic databases,
including SciFinder, Mendeley, and PubMed. The latter was the main source of information,
due to its specificity in the biomedical field.
2. Discussion
Searching for the word “coumarin” in Mendeley, PubMed, and SciFinder in early
November 2020, and filtering by year “2020”, more than a thousand references appeared.
Another search was conducted in late December to include as much information as possible
in this manuscript. A diversity of journals from different fields publishes research articles
and reviews related to the biological interest of both plant extracts containing coumarins
and/or synthetic molecules based on this scaffold. Hybrid molecules containing different
pharmacophores [2,3] like piperazines or pyrazolines [4] are at the top of the list. For
simplicity, in the current review the information is organized taking into account the
potential pharmacological/biological applications of coumarin derivatives.
2.1. Anticancer Activity
The activity of coumarins as anticancer agents is at the top of reviews published in
2020 [5–8], as well as research papers. Potent inhibitors (Figure 2, general structure I) of
aldo–keto reductase (AKR) presenting an iminocoumarin scaffold, with activities between
25 and 56 nM, have been described for the treatment of prostatic cancer [9]. The design
of sulfamide 3-benzylcoumarin hybrids bearing an oxadiazole ring at position 7 (Figure 2,
general structure II) has allowed the preparation of new multitarget mitogen-activated
protein kinase (MEK) inhibitors and nitric oxide (NO) donors, both with antiproliferative
properties [10]. In other cases, the anticancer profile has been directed to other targets. Such
is the case of new inhibitors of cyclin-dependent kinases, specifically CDK9, designing hy-
brids that incorporate an aminopyrimidine fragment to coumarin, both pharmacophores of
known activity on these therapeutic targets [11]. We highlight here compound III (Figure 2),
with high activity and selectivity for these receptors in comparison with other kinases.
Other important targets for cancer treatment, especially lymphomas, are histone
deacetylases (HDACs). A series of coumarins (Figure 2, general structure IV) exhibiting a
hydroxamate structure similar to HDACi vorinostat (SAHA) has been published [12]. The
compounds show inhibitory activity in the nanomolar range, being higher in the case of
propyl or methoxypropyl derivatives.
In addition, it is worth highlighting the design of hybrids in which one part of
the molecule provides fluorescent properties, and another provides therapeutic action
(theranostic). Such is the case of the fusion of a 7-aminocoumarin fluorescent ring with a
chalcone fragment (Figure 2, compound V). This molecule is an inhibitor of thioredoxin
reductases (TrxRs), presenting high antitumor activity (IC50 = 3.6 µM), and is also used as
a diagnostic agent [13]. Coumarin scaffold fluorescence is being explored extensively in
biomedicine, as described at the end of this review.
The preparation of photo-triggered drug delivery systems (PTDDSs, Figure 2, general
structure VI) has also been described, in which the chlorambucil pharmacophore is incor-
porated into more complex carbazole–coumarins (electron donor and electron acceptor
fragments, respectively), carriers of a mitochondrial triphenylphosphonium ligand. This
system allows, by irradiation, the controlled release of the chemotherapeutic agent [14].
Finally, coumarins are widely used as ligands in the formation of metal complexes, as
described in a very recent review [15] focusing on their application as anticancer agents.
Such is the case of complexes with platinum, palladium, gold, copper, or ruthenium, many
of which are also used as described below, in the design of antimicrobial agents.
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Within the group of compounds with anticancer activity, coumarins exhibiting an
antiglioma profile may be highlighted. Simple coumarins such as osthole, umbellifer-
one, esculin, and 4-hydroxycoumarin, combined with sorafenib (a kinase inhibitor drug
approved for the treatment of primary kidney cancer, advanced primary liver cancer, FLT3-
ITD positive acute myeloid leukemia (AML), and radioactive iodine-resistant advanced
thyroid carcinoma) were studied [16]. The same group also studied a combination of the
same simple coumarins with temozolomide (used in the treatment of brain tumors such as
glioblastoma multiforme or anaplastic astrocytoma) [17].
2.2. Antimicrobial Activity
There is also an abundant bibliography related to the interest of coumarins as an-
timicrobials. Most of the projects are still inspired by the classic antibiotic novobiocin.
There are several works in which antibacterial activity is found due to the presence of
an azole ring introduced in different positions of the coumarin system. Articles have
been published recently on the antibacterial activity of azole–coumarins, as well as 3/4/7
substituted arylcoumarins (Figure 3, general structures VII and VIII), especially active
on Gram-positive and negative bacteria according to substitution patterns [15,18–20]. In
other cases, thiazolidinedione–coumarin hybrids have been described (Figure 3, general
structure IX) that show activity on methicillin-resistant Staphylococcus aureus (MRSA) [21].
Interestingly, coumarin metal complexes also show antibacterial activity. Such is the
case of 3-arylcoumarins that present general structures X (Figure 3), coordinated with
Re(I), active against MRSA in nanomolar concentrations [22]; or the complexes of general
structure XI, a coordination of coumarin–quinoline hybrids with Cu(I), with ctivity against
Flavobacterium psychrophilum, a Gram-negative bacterium that causes significant septicemia
in fish, cau ing devastating economic problems in aquaculture [23].
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In addition to the antibacterial activity, in a recent and comprehensive revie on
cou arins, activity against protozoa of the genus Leishmania was described [24]. The ost
pro ising co pounds are prenylated, glycosylated, furan/pyranocou arins, or si ple
hydroxy- or ethoxy-substituted cou arins, along with the natural cou arin ma ea
A/BB (Figure 3, structure XII). Derivatives of this natural product have been prepared and
substitutions at positions 6 and 8, as well as the phenyl ring at position 4, turned out to
be mandatory for the studied activity. This structure–activity relationship (SAR) study
led to the synthesis of the simplest and most lipophilic analogue XIII (Figure 3), the most
promising member of the group as an antileishmanial agent. Similar structures, some also
derived of the Mammea genus, have been evaluated against Mycobacterium tuberculosis, an
activity that also shows simpler synthetic analogues derived from 4-hydroxycoumarin
(Figure 3, general structure XIV) [25].
Finally, it is worth mentioning two articles reported this year on the design and
preparation of coumarin derivatives with potential antiviral activity. This is the case of the
dual hybrid inhibitors inspired by the antiviral activity of calanolide, known as reverse
transcriptase (RT) inhibitor. With this in mind, dual inhibitors of HIV-1 RT and protease
(PR) have been designed, in which the coumarin fragment responsible for RT activity is
linked to the fragment of the antiretroviral darunavir, active against PR of the HIV, through
different amide, carbamate, or amine linkers (Figure 3, general structure XV) [26]. The
second case described the introduction of a piperidine ring through a linker in position 7 of
the coumarin scaffold, originating compounds with outstanding activity against certain
filoviruses such as Marburg virus (MARV) or Ebolavirus (EBOV). From the SAR studied, it
is interesting to highlight the role of substitution in para position with a trifluoromethoxy
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group that originated compound XVI (Figure 3) with IC50 = 0.5 µM and 1.2 µM against
EBOV and MARV, respectively [27].
2.3. Antioxidant and Anti-Inflammatory Activities
Although we have found very few publications related to these activities, in some cases
the antioxidant activity of coumarin derivatives of both natural [28] and synthetic [29]
origin has been reported. This is the case of NOs inhibitors, an activity described for
coumarins that bind through different linkers to phenolic fragments capable of acting as
radical scavengers (Figure 4, general structure XVII), hybrids that can therefore be used in
the treatment of immunomodulatory diseases.
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Figure 4. S ructures of coumarin der atives as antioxid t and a ti-inflammatory agents.
Regarding the anti-inflammatory activity, it is worth mentioning a review on the
coumarins of natural origin (simple coumarins, prenylcoumarins, furocoumarins, coumes-
tans, and benzocoumarins) with a detailed anti-inflammatory activity due to the activation
of the nuclear factor erythroid 2-related factor 2 (Nrf2 factor) that protects cells against
stress oxidative [30]. In other cases, the anti-inflammatory activity found for coumarin
esters (Figure 4, general structure XVIII) as inhibitors of the Kallikrein-related peptidase
9 (KLK9) involved in inflammatory processes of the skin is reported [31]. Finally, the
replacement of the carboxylic group by a sulfone or sulfoxide group (Figure 4, general
structure XIX) gives rise to new inhibitors of cyclooxygenase-2 (COX-2) with activities
comparable, in many cases, to indomethacin [32].
2.4. Adenosine Ligands
The affinity of the coumarin system for adenosine receptors has also been published
recently. The 3-arylcoumarins (Figure 5, compound XX) have been described as antagonists
of hA3 receptors, showing a high affinity (in the low nanomolar range) and selectivity for
this subtype [33], while the 3-aroylcoumarins (Figure 5, general structure XXI) have been
described as dual hA1/hA3 antagonists in the low micromolar range [34]. These works
are aligned with the already known potential of these derivatives as modulators of the
different adenosine receptors, publ shed i the last decade.
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2.5. Enzymatic Inhibitory Activity: α-Glucosidase, Carbonic Anhydrase, Tyrosinase, Sulfatase, and
Xanthine Oxidase
The activity of coumarin derivatives on α-glucosidase was also reviewed in 2020 [35],
in a study in which the influence of the substitution pattern was evaluated, and an
important SAR was established. In addition to α-glucosidase, aldehyde dehydroge-
Molecules 2021, 26, 501 6 of 15
nase 1A1 (ALDH1A1) is another target for the treatment of diabetes and obesity, and
3-amidocoumarins have been described as inhibitors of this enzyme, with compound XXII
(Figure 6) being a very promising derivative (IC50 = 3.87 mM) [36]. This activity has also
recently been found for hybrids of coumarin and cinnamic acid, with compound XXIII
(Figure 6) being described as a very promising derivative (IC50 = 12.98 mM) [37].
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Closely related to these structures, works have been published on coumarin deriva-
tives with inhibitory activity on carbonic anhydrase IX and XII. These are coumarins that
incorporate arylacrylamide substituents at position 3 (Figure 6, general structure XXIV)
that showed inhibitory activity in the nanomolar range [38]. In other cases, anhydrase
inhibitory activity was reported for hybrids connected by a methyleneoxy linker at position
7, oxadiazole heterocycles [39] that the same authors extend to the triazole ring (Figure 6,
general structure XXV) [40].
These last structures are closely related to others that present tyrosinase inhibitory
activity in the sub-micromolar range. This is the case of coumarins (umbelliferone and
other phenolic analogues) that incorporate a kojic acid fragment through a triazole linker
at position 4 (Figure 6, compound XXVI), both fragments with demonstrated tyrosinase
inhibitory activity [41].
Likewise, the introduction of a sulfamate group in the coumarin scaffold originates a
hybrid prototype (Figure 6, general structure XXVII) that presents a high inhibitory activity
of the steroid sulfatase (best compound of the series with IC50 = 0.13 µM), which is of
interest in the treatment of hormone-dependent breast cancers [42].
During 2020, 3-phenylcoumarins were also studied as xanthine oxidase inhibitors [43].
Methoxy and nitro substituents were introduced into the framework. The best compound
in the series proved to be 3-(4-methoxyphenyl)-6-nitrocoumarin, with an IC50 = 8.4 µM,
being also non-cytotoxic in B16F10 cells.
2.6. Anti-Neurodegenerative Diseases Activity: MAO and AChE/BChE Inhibitors
The role played by coumarin derivatives as agents that exhibit biological activities
associated with neurodegenerative diseases, such as Alzheimer’s disease, is very important.
Throughout this year, a large number of manuscripts related to this field have been found.
Due to the multidirectional nature of these diseases, there are also many works on hybrid
coumarins directed at different pharmacological targets, such as monoamine oxidase B
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(MAO-B) or acetylcholinesterase (AChE), amyloid aggregation, or oxidative stress, among
others. Hybrids of general structure XXVIII (Figure 7) have been described, in which
the rasagiline fragment with MAO-B inhibitory activity and neuroprotection properties is
incorporated into the coumarin scaffold also with demonstrated MAO-B inhibitory activity,
antioxidant, and neuroprotective properties [44]. The incorporation at position 3 of a
pyridazine ring (Figure 7, general structure XXIX) is another case of hybrid structures
as selective MAO-B inhibitors [45]. The incorporation of isoxazole-type heterocycles in
carboxamide–coumarins (Figure 7, general structure XXX) allowed obtaining derivatives
with significant inhibitory activities of AChE/BuChE and beta-secretase 1 (BACE1) [46]. In
other cases, taking into account the importance of metals in the pathogenesis of Alzheimer’s
disease, a pyridinone fragment (Figure 7, general structure XXXI) with iron-chelating
properties was incorporated [47].




Figure 7. Structures of coumarin derivatives as anti-neurodegenerative diseases agents. 
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Other multitarget structures are the benzotriazole–coumarin (Figure 7, general struc-
ture XXXII) and carbazole–coumarin (Figure 7, general structure XXXIII) hybrids [48,49].
In both cases, the molecules show antioxidant activity, as well as AChE and β-amyloid
aggregation inhibitory properties. Finally, it is worth mentioning another type of hy-
brid, this time a furocoumarin that incorporates two fragments of resveratrol (Figure 7,
general structure XXXIV) [50]. Compounds containing this scaffold present AChE and
BACE1 inhibitory properties related to the furocoumarin fragment, and antioxidant (radical
scavenging) and COX-2 inhibition, related to the resveratrol [50].
The 7-amidocoumarins (Figure 7, general structure XXXV) have recently been pub-
lished for their potential against monoamine oxidase A (hMAO-A), hMAO-B, hBACE1,
hAChE, and butyrylcholinesterase (hBuChE) [51]. The research project is based on a screen-
ing of compounds with potential activity against Alzheimer’s and Parkinson’s diseases,
since these multifactorial pathologies share some of their pharmacological targets. Five
derivatives of the studied series were described as potent and selective hMAO-B inhibitors
in the nanomolar range; six turned out to be hMAO-A inhibitors in the low micromolar
range; one showed inhibitory activity of hBACE1, and another one hAChE inhibitory
activity, both in the micromolar range. In addition to the enzymatic inhibition, all of the
studied molecules proved to be non-cytotoxic to neurons in the motor cortex. As a main
conclusion, results suggest that by modulating the substitution pattern at position 7 of the
scaffold, selective or multitarget molecules can be achieved.
The 3-arylcoumarins are a family of compounds with proven activity on different
targets related to neurodegenerative diseases, especially Alzheimer’s and Parkinson’s
diseases, the two most prevalent. In the last decade, several manuscripts described very
promising activities of this scaffold, both as selective and multitarget compounds. SAR
studies were performed, and important conclusions were drawn based on the substitution
patterns in the main scaffold. Due to the large number of molecules based on this scaffold
currently synthetized and studied as hMAO inhibitors, in 2020 a theoretical work was
published comparing different QSAR models and docking calculations, in order to predict
the hMAO-B activity of the 3-arylcoumarins [52]. Based on the predictions, a small series
of compounds was synthetized and evaluated against both hMAO-A and hMAO-B, and
the most promising models were validated. Selective activities were found in the low
nanomolar range against this isoenzyme for 6 and 8 methyl-substituted 3-arylcoumarins,
also presenting methoxy groups or bromine atoms in different positions of the 3-phenyl
ring (Figure 7, general structure XXXVI). These advancements may represent robust tools
in the design of potent and selective derivatives.
Analogues of 3-phenylcoumarins were also published during 2020. The discovery
and optimization of 3-thiophenylcoumarins (Figure 7, general structure XXXVII) as novel
and promising agents against Parkinson’s disease have been described [53]. This study
explores, for the first time, the potential of these structures as in vitro and in vivo agents
against this disease. The inhibitory activities of hMAO-A and hMAO-B, antioxidant pro-
file, neurotoxicity in neurons of the motor cortex, and neuroprotection against hydrogen
peroxide production were studied. The in vivo effect on locomotor activity was also eval-
uated by an open field test (OFT) for the most potent, selective and reversible hMAO-B
inhibitor of the series: 3-(4′-bromothiophen-2′-yl)-7-hydroxycoumarin (IC50 = 140 nM). In
reserpinized mice pre-treated with levodopa and benserazide, this molecule exhibited a
slightly better in vivo profile than selegiline, currently a therapeutic option for Parkinson’s
disease. The results suggested that the 7-position substitution of the coumarin scaffold is
interesting for enzyme inhibition. Furthermore, the presence of a catechol at positions 7
and 8 exponentially increases the antioxidant potential and the neuroprotective properties.
The neuroprotective effects of xanthotoxin and umbelliferone on streptozotocin (STZ)-
induced cognitive dysfunction in rats were evaluated [54]. Alzheimer’s disease was
induced in these animals and both compounds were administrated, proving to prevent
cognitive deficits in the Morris water maze and object recognition tests. In addition, both
compounds reduced the activity of hippocampal AChE and the level of malondialdehyde,
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increasing the glutathione content. These coumarins also modulated neuronal cell death
by reducing the level of proinflammatory cytokines, inhibiting the overexpression of
inflammatory markers (nuclear factor κB and cyclooxygenase II), and upregulating the
expression of NF-κB inhibitor (IκB-α). An attenuation of cognitive dysfunction by these
compounds was observed. This effect can at least be attributed to the inhibition of AChE
and the reduction of oxidative stress, neuroinflammation, and neuronal loss, opening a
new door for these classic coumarins.
2.7. Anticoagulant Activity
The classic anticoagulant effect of specific coumarin derivatives, based on aceno-
coumarol and warfarin, also remains one of the classic applications for this family. During
2020, a review on this topic was published [55].
2.8. Fluorescent Probes
In addition to the interest of coumarins as a versatile scaffold in drug design, the
important role that this scaffold plays as fluorescent probes to detect metals, enzymes, and
biomaterials, among others, should be highlighted [56–59]. These fluorescent probes have
a great imaging potential for the diagnosis of several pathologies.
Coumarins are being used in the selective detection of metals such as copper (Figure 8,
general structure XXXVIII) [60] or its determination in drinking water (Figure 8, com-
pound XXXIX) [61,62]. A recent review focuses on the detection of iron in water and its
applications [63]. Other works study the fluorescence determination of the presence of
silver in aqueous medium (Figure 8, compound XL) [64]. In the case of mercury, there are
also published works in which the selective determination in water is studied (Figure 8,
general structure XLI) [65]. In some cases, this determination is selective, but in this case,
the innovative methodology can be applied over a wide pH range (Figure 8, compound
XLII) [66].
In some cases, these metal complexes serve as probes for the detection of biothiols, as
in the case of copper complexes with benzothiazoles (Figure 8, compound XLIII) used in
the determination of cysteines [67], or coumarin–quinoline complexes used in the detection
of glutathione (Figure 8, compound XLIV) [68]. In other cases, aromatization to form
the coumarin ring is used as a fluorescence test to detect the superoxide anion (Figure 8,
compound XLV) [69].
In addition to the determination of metals, in many cases coumarin derivatives are
used as fluorescence probes for the detection of hypochlorite, as in the case of coumarin–
thiophene complexes (Figure 8, compound XLVI) [70] or of 2-thiocoumarins in which the
presence of ClO– allows the formation of a fluorescent coumarin (Figure 8, compound
XLVII) [71].
Coumarins can also be used as photocleavable linkers in the controlled release of drugs
or biomaterials. This is the case of the in vivo photolysis of the microtubule inhibitor 4-
pyridinomethylcoumarin (Figure 8, compound XLVIII) [72]. 7-Hydroxymethyl substituted
aminocoumarins are used as iron complexes (Figure 8, general structures XLIX and L),
and can be used to photochemotherapeutically target the mitochondria in the treatment of
cancer [60,73].
Other reviews report on the use of 7-hydroxycoumarin and its derivatives in deter-
mining the activity of cytochromes P450 (CYP) enzymes [74] as well as 7-aminocoumarin
derivatives in determining amino acids from serine or cysteine proteases [58]. In other
cases, they are used to detect the metabolism of mitochondrial cysteines, the oxidation of
which is a measure of cellular oxidative stress (Figure 8, compound LI) [75]. The use of
the chiral coumarin-BINOL hybrid allows the enantioselective detection of amino acids
(Figure 8, compound LII) [76]. Finally, coumarins can be used for easy detection of bacterial
carbapenamases in which the coumarin fluorophore binds to the carbapenemic structure
via a reactive linker (Figure 8, general structure LIII) [77,78].
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3. Perspectives
Coumarins are privileged structures for biological applications. Their conjugated
double ring system allows different spots for chemical modifications, and a large number
of derivatives can be obtained. Therefore, structure/activity studies appear to be the
hottest emerging topic. During the year 2020, more than a thousand research articles and
reviews related to coumarins could be found. This highlights the great potential that these
molecules can have in different fields of research. For simplicity, our overview focused
on the potential of coumarins in medicinal chemistry. The most relevant studies were
included. The range of applications described in this document, and some others outside
the scope of this general description (i.e., optoelectronic applications [79], polymers [80],
etc.), reflect the versatility of this scaffold.
In our opinion, the potential of coumarins as fluorescent probes appears to be the
most promising field of research for the next few years, since several coumarin derivatives
have shown great potential in prodrug degradation (drug release) and diagnostics.
Due to the length of this general overview, synthetic strategies for obtaining new
coumarins have not been discussed in detail. To find information on the most recent
synthetic pathways, we recommend the manuscripts by Molnar and co-authors [81] and
Kovač and co-authors [82], both from 2020. To find an overview of the wide range of
biological activities of coumarins, a 2020 review by Pinto and co-authors [1] is strongly
recommended. Finally, to find information on the most recent analytical methods (fun-
damentals, instrumentation, purification and quantification applications, optimization of
experimental conditions, emerging ecological methods, etc.) we recommend the review by
Xue-song and co-authors [83].
4. Conclusions
Coumarins belong to a privileged family for biomedical proposes. Their simplicity,
chemical properties, and the efficiency of the synthetic routes to obtain a wide range of
substitution patterns make these compounds highly attractive and versatile for medicinal
and biological chemists. To date, and during 2020, more than a thousand research articles
and reviews containing information on coumarins appear in the PubMed, SciFinder, and
Mendeley databases. The number of research groups working on this scaffold, and the
impact of the results, highlight the potential of these molecules. Special attention has been
paid to the potential of coumarins in drug design, as well as to fluorescent probes. This
last application seems to be the most promising field of research for the next few years,
since several coumarin derivatives have shown great potential in the decaging of prodrugs
(drug release) and for diagnostic purposes.
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